Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy:  expanding the groups at risk.

D, Parakkal; H, Sifuentes; R, Semer; ED, Ehrenpreis

doi:10.1097/meg.0b013e32834bb90a

Public

Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.

Shared by NobleBlocks on Nov 1, 2011 • 12:00 AM UTC

Authors:

Parakkal D

Sifuentes H

Semer R

Abstract

Background Hepatosplenic T-cell lymphoma (HSTCL) is a rare, lethal disease generally seen in young male patients with inflammatory bowel disease. The study of biologic and immunomodulator naive patients in Crohn's disease (SONIC), advocates combining infliximab with an immunomodulator in moderate-to...

Discussions